WASHINGTON, United States – The US Food and Drug Administration on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in mild and early stages of Alzheimer’s disease. (FILES) This file photo taken on March 18, 2017, shows a sign for biotechnology company Biogen, Inc. ...